SPRAVATO (Intranasal Esketamine) is the new FDA approved treatment for Treatment-resistant Depression indicated for patients who have failed two adequate trials of other antidepressant medications. To learn more about this treatment, please visit https://www.spravato.com.
How Is SPRAVATO™ Different?
HOW ORAL ANTIDEPRESSANTS WORK
Today’s most commonly used oral antidepressants are thought to treat depression by increasing levels of neurotransmitters (serotonin, norepinephrine and dopamine) in areas of the brain that affect mood.
HOW SPRAVATO™ MAY WORK DIFFERENTLY
SPRAVATO™ targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. The exact way that SPRAVATO™ works is unknown. SPRAVATO™ is taken with a daily oral antidepressant.
Spravato™ Nasal Spray
The FDA has now approved the first drug that can relieve depression in hours instead of weeks. In a recent article titled “FDA Approves Esketamine Nasal Spray For Hard-To-Treat Depression,“ NPR stated:
“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” said Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, in a press release about the decision.
‘This is potentially a game-changer for millions of people,’ said Dr. Dennis Charney, Dean of the Icahn School of Medicine at Mount Sinai in New York. ‘It offers a lot of hope.’”
Spravato™ (esketamine) Recommended Treatment Protocols / Pricing:
Most insurance companies are now covering Spravato therapy; with a referral, our insurance coordinator can assist with your preauthorization.